Skip to content

Newborn screening and precision medical system construction for primary immunodeficiency disease

Newborn screening and precision medical system construction for primary immunodeficiency disease

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032139
Enrollment
Unknown
Registered
2020-04-20
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary immunodeficiency

Interventions

Gold Standard:1. Whether there is immune deficiency
2. Primary or secondary, persistent or temporary
3. The part and degree of the defect of immune system
4. Molecular diagnosis: sequence the first / second generation genes to detect whether there is pathogenic gene mutation
detection of relative protein molecular.
Index test:PID&#32
newborn&#32
screening&#32
technology&#32
system&#32
based&#32
on&#32
TRECs/KRECs&#32
combined&#32
with&#32
quantitative&#32
detection

Sponsors

Children's Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: A sample of dry blood spot was screened in the clinical molecular center of children's Hospital Affiliated to Chongqing Medical University Neonatal dry blood tablets: 1. Unlimited gestational age and birth weight; 2. Heel blood collected 72 hours after birth; 3. The transportation time of dried blood tablets is within 1 month; 4. Three blood spots are complete and even.

Exclusion criteria

Exclusion criteria: 1. The transport time of blood tablets exceeds 1 month; 2. Incomplete and uneven blood spots.

Design outcomes

Primary

MeasureTime frame
TREC;KREC;

Countries

China

Contacts

Public ContactXiaodong Zhao

Children's Hospital Affiliated to Chongqing Medical University

zhaoxd530@aliyun.com+86 23-63620602

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026